Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 14/20 | 0.77 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.77 |
| ▸ | CDK2 | P24941 | 3/20 | 0.77 |
| ▸ | LCK | P06239 | 2/20 | 0.77 |
| ▸ | RET | P07949 | 2/20 | 0.77 |
| ▸ | FLT3 | P36888 | 2/20 | 0.77 |
| ▸ | MUSK | O15146 | 1/20 | 0.77 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.77 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.77 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.77 |
| ▸ | JAK2 | O60674 | 15/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.58 |
| ▸ | STAT5B | P51692 | 1/20 | 0.58 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.58 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.58 |
| ▸ | AURKA | O14965 | 3/20 | 0.45 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.45 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422468 | 1.00 | JAK3 (0.77) | JAK3NTRK1CDK2LCKRET | |
| SCHEMBL23217032 | 0.90 | JAK3 (0.62) | JAK3NTRK1CDK2LCKRET | |
| SCHEMBL3420176 | 0.90 | JAK3 (0.62) | JAK3NTRK1CDK2LCKRET | |
| SCHEMBL30009943 | 0.90 | JAK3 (0.62) | JAK3NTRK1CDK2LCKRET | |
| SCHEMBL2513814 | 0.88 | JAK3 (0.59) | JAK3NTRK1CDK2LCKRET | |
| SCHEMBL10027491 | 0.87 | JAK3 (0.58) | JAK3NTRK1CDK2LCKRET | |
| SCHEMBL31061147 | 0.87 | JAK3 (1.00) | JAK3NTRK1CDK2LCKRET | |
| SCHEMBL14840663 | 0.87 | JAK3 (1.00) | JAK3NTRK1CDK2LCKRET | |
| SCHEMBL14840664 | 0.87 | JAK3 (1.00) | JAK3NTRK1CDK2LCKRET | |
| SCHEMBL2486709 | 0.87 | JAK3 (0.75) | JAK3NTRK1CDK2LCKRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140045895-A1 | PHARMACEUTICAL DEPOT FOR 5-FLUORO-2-[[(1S)-1-(5-FLUORO-2-PYRIDYL)ETHYL]AMINO]-6-[(5-ISOPROPOXY-1H-PYRAZOL-3-YL)AMINO]PYRIDINE-3-CARBONITRILE | ASTRAZENECA AB (SE) | 2014-02-13 | — | — | US | claimed |
| US-8324252-B2 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | ASTRAZENECA AB (SE) | 2012-12-04 | — | — | US | claimed |
| US-20120022110-A1 | PHARMACEUTICAL DEPOT FOR 5-FLUORO-2-[[(1S)-1-(5-FLUORO-2-PYRIDYL)ETHYL]AMINO]-6-[(5-ISOPROPOXY-1H-PYRAZOL-3-YL)AMINO]PYRIDINE-3-CARBONITRILE | ASTRAZENECA AB (SE) | 2012-01-26 | — | — | US | claimed |
| EP-1846394-B1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-10-26 | — | — | EP | claimed |
| US-20080139561-A1 | e.g. 6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino) nicotinonitrile; tropomyosin-related kinases (Trk's) inhibitor; anticarcinogenic agent; hormone related cancer, leukemia; antiinflammatory agent; arthritis, restenosis; autoimmune diseases | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | US | claimed |
| US-20080108669-A1 | Use 541 | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | claimed |
| US-20240158756-A1 | FEEDER-BASED AND FEEDER-FREE STEM CELL CULTURE SYSTEMS FOR STRATIFIED EPITHELIAL STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-05-16 | — | — | US | disclosed |
| CN-114945378-A | Feeder-layer and feeder-layer-free stem cell culture systems for stratified epithelial stem cells and uses related thereto | 休斯敦大学体系 | 2022-08-26 | — | — | CN | disclosed |
| US-20210164055-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| US-10907215-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | LOXO ONCOLOGY, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10724102-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | LOXO ONCOLOGY, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10655186-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | LOXO ONCOLOGY, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-10378068-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | LOXO ONCOLOGY, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20120022110-A1 | PHARMACEUTICAL DEPOT FOR 5-FLUORO-2-[[(1S)-1-(5-FLUORO-2-PYRIDYL)ETHYL]AMINO]-6-[(5-ISOPROPOXY-1H-PYRAZOL-3-YL)AMINO]PYRIDINE-3-CARBONITRILE | ASTRAZENECA AB (SE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022110-A1 | PHARMACEUTICAL DEPOT FOR 5-FLUORO-2-[[(1S)-1-(5-FLUORO-2-PYRIDYL)ETHYL]AMINO]-6-[(5-ISOPROPOXY-1H-PYRAZOL-3-YL)AMINO]PYRIDINE-3-CARBONITRILE | ASTRAZENECA AB (SE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022110-A1 | PHARMACEUTICAL DEPOT FOR 5-FLUORO-2-[[(1S)-1-(5-FLUORO-2-PYRIDYL)ETHYL]AMINO]-6-[(5-ISOPROPOXY-1H-PYRAZOL-3-YL)AMINO]PYRIDINE-3-CARBONITRILE | ASTRAZENECA AB (SE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022110-A1 | PHARMACEUTICAL DEPOT FOR 5-FLUORO-2-[[(1S)-1-(5-FLUORO-2-PYRIDYL)ETHYL]AMINO]-6-[(5-ISOPROPOXY-1H-PYRAZOL-3-YL)AMINO]PYRIDINE-3-CARBONITRILE | ASTRAZENECA AB (SE) | 2012-01-26 | — | — | US | disclosed |
| EP-2164490-A1 | PYRAZOLYL DERIVATIVES WITH ANALGESIC ACTIVITY AND THEREFORE USEFUL IN THE TREATMENT OR PROPHYLAXIS OF PAIN. | AstraZeneca AB (SE) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008054292-A1 | PYRAZOLYL DERIVATIVES WITH ANALGESIC ACTIVITY AND THEREFORE USEFUL IN THE TREATMENT OR PROPHYLAXIS OF PAIN. | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | WO | disclosed |
| US-20080108669-A1 | Use 541 | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139561-A1 | e.g. 6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino) nicotinonitrile; tropomyosin-related kinases (Trk's) inhibitor; anticarcinogenic agent; hormone related cancer, leukemia; antiinflammatory agent; arthritis, restenosis; autoimmune diseases | CNKSR1, LTK, MUSK | JAK3 697/4885NTRK1 86/4885CDK2 113/4885 |
| US-10907215-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | NTRK3, NTRK1, NTRK2 | JAK3 1275/4885NTRK1 2/4885CDK2 829/4885 |
| US-20210164055-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | JAK3 1324/4885NTRK1 2/4885CDK2 830/4885 |
| US-20120022110-A1 | PHARMACEUTICAL DEPOT FOR 5-FLUORO-2-[[(1S)-1-(5-FLUORO-2-PYRIDYL)ETHYL]AMINO]-6-[(5-ISOPROPOXY-1H-PYRAZOL-3-YL)AMINO]PYRIDINE-3-CARBONITRILE | PNN, PCNP, PCK1 | JAK3 1295/4885NTRK1 3329/4885CDK2 2205/4885 |
| US-10655186-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | NTRK3, NTRK1, NTRK2 | JAK3 1324/4885NTRK1 2/4885CDK2 830/4885 |
| US-10378068-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | NTRK3, NTRK1, NTRK2 | JAK3 1324/4885NTRK1 2/4885CDK2 830/4885 |
| US-20080108669-A1 | Use 541 | TRPV1, P2RX3, P2RX5 | JAK3 2868/4885NTRK1 3837/4885CDK2 4346/4885 |
| US-10724102-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | NTRK3, NTRK1, NTRK2 | JAK3 1324/4885NTRK1 2/4885CDK2 830/4885 |
| US-20140045895-A1 | PHARMACEUTICAL DEPOT FOR 5-FLUORO-2-[[(1S)-1-(5-FLUORO-2-PYRIDYL)ETHYL]AMINO]-6-[(5-ISOPROPOXY-1H-PYRAZOL-3-YL)AMINO]PYRIDINE-3-CARBONITRILE | PNN, PCNP, PCK1 | JAK3 1295/4885NTRK1 3329/4885CDK2 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.